Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs
Humacyte, Inc., a biotech company specializing in bioengineered human tissues, announced that its FDA-approved product Symvess is now under contract with the U.S. Department of Veterans Affairs Strategic Acquisition Center (SAC). This contract streamlines Symvess's accessibility and approval process across 170 VA hospitals, enhancing treatment opti…